TABLE 2

Demographic and oncologic characteristics of patients with or without transient or persistent cardiac troponin isoform I (cTnI) elevations

CharacteristicscTnI− (n = 51)cTnI+ (n = 16)P (cTnI− vs. cTnI+)
Age (yr)49 (41–56)52 (47–58)0.143
Gender (n, %)
male9 (18%)2 (13%)0.435
female42 (82%)14 (87%)
Oncologic disease (n, %):
breast cancer32 (63%)11 (69%)0.001
non-Hodgkin lymphoma12 (23%)5 (31%)
colorectal cancer7 (14%)0
Chemotherapy (n, %):
anthracycline-based,a44 (86%)16 (100%)<0.0001
nonanthracyclineb7 (14%)0
Anthracycline dose (mg/m2)c240 (240–300)240 (240–300)0.465
Taxane administration (n, %)29 (57%)11 (69%)0.185
  • cTnI− or cTnI+ denotes the absence or presence of cTnI elevations.

  • Values are medians with interquartile ranges. Differences were analyzed by two-tailed Mann-Whitney test, χ2 test, or Fisher’s exact test as appropriate.

  • a For breast cancer: doxorubicin (or epirubicin)/cyclophosphamide once every 3 weeks (four cycles), followed by taxane once every 3 weeks (four cycles); 5-fluorouracil/epirubicin/cyclophosphamide once every 3 weeks (six cycles); 5-fluorouracil/epirubicin/cyclophosphamide once every 3 weeks (four cycles), followed by taxane once every 3 weeks (four cycles); epirubicin/cyclophosphamide/taxane once every 3 weeks (four cycles). For non-Hodgkin lymphoma: rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone once every 3 weeks (six cycles).

  • b Folinate/5-fluouracil/oxaliplatin once every 2 weeks (12 cycles); capecitabine (orally)/oxaliplatin once every 3 weeks (eight cycles).

  • c Doxorubicin myelotoxic equivalents.